Episode 47

1

Introduction

00:00 • 2min

2

M&A and the Inflation Reduction Act

01:32 • 2min

3

Medicare Advantage - The Most Profitable Insurance Product on the Market?

03:21 • 4min

4

Oncology - Is There an Opportunity?

07:22 • 2min

5

Biotech Companies Competing With Each Other

08:58 • 2min

6

Is There a Sweet Spot for Validated Targets in the Innovation Space?

10:29 • 3min

7

What We Learned This Week About Obesity Drugs

13:04 • 2min

8

A Look at Regeneron and Cosympto in COPD

15:19 • 5min

9

Pharma - The Fensives Are Over and Pharma Is Going to Suffer

20:26 • 2min

10

Biotech

22:12 • 2min

11

I'm Sorry, George Has Got Something to Say on That.

23:47 • 2min

12

The Therapeutic Melanoma Partnership - Is That Really What They Think?

25:49 • 2min

13

Biosimilars and Humira - What's Going On?

27:24 • 3min

14

Humira Biosimilars Aren't Offering Meaningful Market Share, Right?

30:14 • 2min

15

Is Medicare Going to Pay Less for Drugs That Receive Accelerated Approval?

32:01 • 2min

16

The FDA Approval of a GSK's Just Do Rock

34:08 • 2min

17

The FDA Approval for Chronic Kidney Disease (CKD)

35:46 • 3min

18

Jarrow Science - A Challenge for Biotech

38:26 • 4min

19

How Do You Think We Should Be Investing in Increasing HealthSpan?

42:05 • 2min

20

Biohackers, I'm a Biohacker, Is There a Moral Implication?

43:39 • 2min

21

Is There a Connection Between Alzheimer's and Obesity?

45:26 • 2min

22

Those Are the Faces of Gyro Science, Right?

47:04 • 2min

23

Is Biohacking a New Thing?

49:12 • 2min

24

Is Silicon Valley Disrupting Biotech?

50:59 • 3min

25

Is the Biotech Industry Changing at a Faster Tempo?

53:51 • 2min

26

Biotech M&A - What's Next?

55:50 • 3min